Mode
Text Size
Log in / Sign up
Phase 4 N=43 Randomized Quadruple-blind Treatment

The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy

Hypertension, Pregnancy-Induced · Pre-eclampsia

Enrolled (actual)
43
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Difference in Systolic Blood Pressure (SBP) — 131.8; 132.0; 129.1; 129.1 mmHg

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Ibuprofen (Drug); Acetaminophen (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
University of Michigan
Primary completion
Mar 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Difference in Systolic Blood Pressure (SBP)
131.8; 132.0; 129.1; 129.1; -2.7; -2.9
SECONDARY
Change in Self-reported Pain Score 2 Hours After First Intervention
-0.6; -0.3; -1.1; 1.0; -0.7; -0.6 0.59
SECONDARY
Mean Pain Score by Nursing Assessment
2.2; 2.3 0.76
SECONDARY
Satisfaction With Pain Control During 24 Hours of Exposure Each to Ibuprofen and Acetaminophen
3; 4; 3; 4.5; 3; 4.5 0.02 sig

Summary

To assess the effect of routine doses of ibuprofen on post-partum blood pressure control in women with gestational hypertension (gHTN) or preeclampsia without severe features (preE).

Eligibility Criteria

Inclusion Criteria

  • Antepartum women
  • Diagnosis of Gestational Hypertension or Pre-eclampsia by blood pressure ≥140 systolic or ≥90 diastolic, on at least 2 measurements ≥ 4 hours apart; with or without proteinuria (urine protein-creatinine ratio ≥0.3 or 24 hour-urine protein ≥300 mg).
  • Taking one or fewer oral medications for blood pressure control.
  • Singleton gestation.
  • English-speaking

Exclusion Criteria

  • Allergy to nonsteroidal anti-inflammatory drugs, aspirin, or acetaminophen
  • More than 1 severe range blood pressure (≥160 systolic or ≥110 diastolic) prior to enrollment.
  • Neurologic symptoms attributed to hypertension (headache, visual changes) prior to enrollment.
  • Pulmonary edema.
  • Elevated AST (>60 international units/L) or ALT (>70 international units/L) prior to enrollment.
  • Low platelet count ( 1.1 or double the baseline creatinine if known) prior to enrollment.
  • Chronic hypertension defined as hypertension pre-existing pregnancy or diagnosed prior to 20-weeks' gestation.
  • Moderate- or severe-persistent asthma.
  • Therapeutic anticoagulation.
  • Chronic opiate use during the pregnancy (opiate therapy given daily for > 2 weeks).
  • Lactose intolerance or allergy due to placebo containing lactose.
  • Cesarean delivery.
  • Additional anesthesia at time of delivery (spinal anesthesia, sedation) that would change routine pain management.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02891174). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search